Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisone in Exogenous Insulin Antibody Syndrome
NCT04357392Phase 1Unknown
- Start
- May 2020
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, double-blind trial in exogenous insulin antibody syndrome (EIAS) comparing Glucocorticoid intervention group with Placebo control group (2 arms). Primary endpoint: Number of patients with HbA1c <7% at 24 weeks. Status: unknown.
02
Drugs
prednisone
03
Conditions
exogenous insulin antibody syndrome (EIAS)
Beyond the preview
Go deeper on NCT04357392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04357392.